Perrigo Company plc (NYSE:PRGO) Shares Sold by Arizona State Retirement System

Arizona State Retirement System lessened its holdings in shares of Perrigo Company plc (NYSE:PRGO) by 1.8% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 37,850 shares of the company’s stock after selling 681 shares during the quarter. Arizona State Retirement System’s holdings in Perrigo were worth $1,218,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. Vanguard Group Inc. grew its position in shares of Perrigo by 1.5% in the 3rd quarter. Vanguard Group Inc. now owns 14,328,895 shares of the company’s stock worth $510,968,000 after acquiring an additional 215,794 shares in the last quarter. BlackRock Inc. grew its position in shares of Perrigo by 4.8% in the 1st quarter. BlackRock Inc. now owns 12,112,154 shares of the company’s stock worth $465,469,000 after acquiring an additional 554,915 shares in the last quarter. Wolf Hill Capital Management LP grew its position in shares of Perrigo by 35.6% in the 2nd quarter. Wolf Hill Capital Management LP now owns 5,367,678 shares of the company’s stock worth $182,233,000 after acquiring an additional 1,408,044 shares in the last quarter. State Street Corp grew its position in shares of Perrigo by 4.8% in the 1st quarter. State Street Corp now owns 4,270,353 shares of the company’s stock worth $164,110,000 after acquiring an additional 193,783 shares in the last quarter. Finally, Goldman Sachs Group Inc. grew its position in shares of Perrigo by 17.6% in the 1st quarter. Goldman Sachs Group Inc. now owns 3,074,409 shares of the company’s stock worth $118,149,000 after acquiring an additional 460,102 shares in the last quarter. Institutional investors and hedge funds own 95.91% of the company’s stock.

Perrigo Trading Down 3.1 %

NYSE:PRGO opened at $30.32 on Monday. Perrigo Company plc has a 12-month low of $25.77 and a 12-month high of $40.28. The firm has a market capitalization of $4.11 billion, a P/E ratio of -303.20 and a beta of 0.64. The company has a debt-to-equity ratio of 0.76, a current ratio of 1.79 and a quick ratio of 1.07. The business has a 50 day simple moving average of $30.80 and a 200 day simple moving average of $30.82.

Perrigo (NYSE:PRGO) last announced its quarterly earnings results on Tuesday, February 27th. The company reported $0.86 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.83 by $0.03. Perrigo had a positive return on equity of 7.34% and a negative net margin of 0.27%. The company had revenue of $1.16 billion during the quarter, compared to analyst estimates of $1.17 billion. During the same quarter in the previous year, the firm posted $0.75 EPS. The firm’s quarterly revenue was up .1% on a year-over-year basis. Equities research analysts predict that Perrigo Company plc will post 2.55 EPS for the current year.

Perrigo Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, March 26th. Shareholders of record on Friday, March 8th were given a dividend of $0.276 per share. This represents a $1.10 dividend on an annualized basis and a yield of 3.64%. The ex-dividend date was Thursday, March 7th. This is a positive change from Perrigo’s previous quarterly dividend of $0.27. Perrigo’s payout ratio is -1,100.00%.

Analyst Ratings Changes

PRGO has been the subject of several research reports. Piper Sandler lifted their target price on Perrigo from $35.00 to $39.00 and gave the stock an “overweight” rating in a research report on Monday, April 8th. StockNews.com upgraded Perrigo from a “hold” rating to a “buy” rating in a research report on Wednesday, April 3rd. Canaccord Genuity Group restated a “buy” rating and set a $42.00 price objective on shares of Perrigo in a research report on Friday. Finally, JPMorgan Chase & Co. reduced their price objective on Perrigo from $48.00 to $41.00 and set an “overweight” rating for the company in a research report on Wednesday, February 28th.

Insiders Place Their Bets

In other Perrigo news, EVP Robert Willis purchased 6,000 shares of Perrigo stock in a transaction on Thursday, February 29th. The stock was bought at an average price of $25.87 per share, for a total transaction of $155,220.00. Following the transaction, the executive vice president now owns 25,105 shares of the company’s stock, valued at approximately $649,466.35. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In other Perrigo news, EVP Robert Willis purchased 6,000 shares of Perrigo stock in a transaction on Thursday, February 29th. The stock was bought at an average price of $25.87 per share, for a total transaction of $155,220.00. Following the transaction, the executive vice president now owns 25,105 shares of the company’s stock, valued at approximately $649,466.35. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Alison Ives acquired 2,490 shares of the business’s stock in a transaction dated Tuesday, March 5th. The stock was purchased at an average price of $27.26 per share, with a total value of $67,877.40. Following the acquisition, the executive vice president now owns 16,122 shares of the company’s stock, valued at $439,485.72. The disclosure for this purchase can be found here. In the last quarter, insiders acquired 17,990 shares of company stock worth $475,227. 0.70% of the stock is owned by company insiders.

About Perrigo

Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers.